Skip to main content

Table 2 Distribution of baseline characteristics of patients collected at registration by treatment administration

From: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

 

Phase 2

Validation

Treated (n = 180)

Not treated (n = 121)

P

Treated (n = 528)

Not treated (n = 360)

P

Geographic area—no. (%)

  

 < 0.001

  

0.30

 Lombardia

94 (52.2%)

42 (34.7%)

 

195 (36.9%)

140 (38.9%)

 

 Veneto

14 (7.8%)

51 (42.1%)

 

28 (5.3%)

12 (3.3%)

 

 Emilia Romagna

29 (16.1%)

8 (6.6%)

 

76 (14.4%)

65 (18.1%)

 

 Other Northern regions

–

–

 

51 (9.7%)

40 (11.1%)

 

 Center

23 (12.8%)

16 (13.2%)

 

107 (20.3%)

61 (16.9%)

 

 South and Islands

20 (11.1%)

4 (3.3%)

 

71 (13.4%)

42 (11.7%)

 

Age—no. (%)

  

0.04

  

0.22

  ≤ 60

79 (43.9%)

43 (35.5%)

 

209 (39.6%)

156 (43.3%)

 

 61–70

67 (37.2%)

40 (33.1%)

 

148 (28.0%)

107 (29.7%)

 

 71 + 

34 (18.9%)

38 (31.4%)

 

171 (32.4%)

97 (26.9%)

 

Female sex—no. (%)

31 (17.2%)

28 (23.1%)

0.20

108 (20.5%)

85 (23.6%)

0.26

Ethnic group—no. (%)

  

0.42

  

0.1

 Caucasian

170 (97.1%)

101 (97.1%)

 

494 (97.4%)

333 (97.9%)

 

 Asiatic

1 (0.6%)

2 (1.9%)

 

2 (0.4%)

0 (0.0%)

 

 Other

4 (2.3%)

1 (1.0%)

 

11 (2.2%)

7 (2.1%)

 

 Unknown

5

17

 

21

20

 

Body Mass Index—no. (%)

  

0.06

  

0.74

 Underweight/normal

40 (24.7%)

35 (35.7%)

 

112 (27.1%)

73 (26.0%)

 

 Overweight/Obese

122 (75.3%)

63 (64.3%)

 

301 (72.9%)

208 (74.0%)

 

 Unknown

18

23

 

115

79

 

Previous/actual smoker—no. (%)

33 (22.4%)

18 (21.7%)

0.89

130 (30.2%)

79 (27.9%)

0.52

 Unknown

33

38

 

97

77

 

Antiflu 2019 vaccination—no. (%)

31 (21.5%)

23 (31.9%)

0.10

75 (21.8%)

44 (18.5%)

0.33

 Unknown

36

49

 

184

122

 

Initial respiratory support– no. (%)

  

0.003

  

< 0.001

 Oxygen supplement

73 (40.6%)

73 (60.3%)

 

223 (42.2%)

223 (61.9%)

 

 NIMV

74 (41.1%)

32 (26.4%)

 

238 (45.1%)

112 (31.1%)

 

 IMV

33 (18.3%)

16 (13.2%)

 

67 (12.7%)

25 (6.9%)

 

PaO2/FiO2 ratio– no. (%)

  

0.08

  

< 0.001

  ≤ 100

36 (33.6%)

19 (30.2%)

 

91 (25.9%)

30 (18.3%)

 

 101–200

53 (49.5%)

23 (36.5%)

 

170 (48.4%)

66 (40.2%)

 

 201–300

14 (13.1%)

18 (28.6%)

 

68 (19.4%)

44 (26.8%)

 

 > 300

4 (3.7%)

3 (4.8%)

 

22 (6.3%)

24 (14.6%)

 

 Unknown

73

58

 

177

196

 

Heart disease—no. (%)

31 (17.8%)

31 (27.4%)

0.053

99 (19.4%)

48 (15.6%)

0.17

 Unknown

6

8

 

18

53

 

Hypertension—no. (%)

92 (52.9%)

55 (48.7%)

0.49

242 (47.5%)

141 (45.9%)

0.67

 Unknown

6

8

 

18

53

 

Diabetes—no. (%)

23 (13.2%)

11 (9.7%)

0.37

84 (16.5%)

51 (16.6%)

0.96

 Unknown

6

8

 

18

53

 

Anti-retroviral—no. (%)

112 (65.1%)

113 (60.2%)

0.40

342 (66.4%)

224 (69.4%)

0.38

 Unknown

8

8

 

13

37

 

Hydroxy-chloroquine—no. (%)

130 (75.6%)

77 (68.1%)

0.17

395 (76.7%)

244 (75.5%)

0.70

 Unknown

8

8

 

13

37

 

Antibiotics—no. (%)

84 (48.8%)

34 (30.1%)

0.002

274 (53.2%)

163 (50.5%)

0.44

 Unknown

8

8

 

13

37

 

Steroids—no. (%)

41 (23.9%)

21 (18.6)

0.29

176 (34.2%)

115 (35.6%)

0.67

 Unknown

8

8

 

13

37

 

LMW heparin—no. (%)

45

221

0.14

116 (22.5%)

57 (17.7%)

0.09

 Unknown

8

8

 

13

37

 

C-reactive protein—median (IQR)

30 (13–116)

73 (17–122)

0.06

31 (14–132)

57 (14–144)

0.38

 Unknown

34

29

 

102

128

Â